About HD ScienceEven though the gene that causes Huntington’s disease was discovered in 1993, there’s still a lot to learn about how it causes disease. And there is still no treatment that can stop or slow down the progress of HD. The Enroll-HD study aims to help fill these gaps by supporting and accelerating HD research.
- May 07, 2019
- Mar 21, 2019
- Mar 14, 2019
- Mar 05, 2019
- Feb 28, 2019
- Feb 27, 2019
Open QuestionsWhen people carry the HD gene mutation their bodies produce a misshapen version of the huntingtin protein (also called HTT) that makes some brain cells function poorly and eventually kills the cells. People are born with the gene, yet most are healthy for many years and only start developing symptoms in mid-life. Scientists don’t fully understand why it takes so long for the gene to make people ill, but it suggests that once we do have effective treatments there is a real possibility that this illness-free period can be prolonged. Every cell in the body produces the expanded huntingtin protein but the real damage is done in just one part of the brain, called the striatum. Researchers don’t understand why the damage is so specific, but it’s thought that the death of cells in the striatum of the brain leads to many of the major signs of illness. Surprisingly, it’s also still not completely clear what the healthy version of the huntingtin protein does, it seems to do lots of different jobs in the cell but its main purpose is not yet defined. To study these questions many scientists use animal models such as mice, rats, sheep or even flies that have been genetically altered to carry the HD disease gene. By working with animal models researchers can do more invasive studies, such as taking biopsies of brain tissue, that aren’t possible in people.
New HopesResearch on the disease moved slowly for many years because HD affects a relatively small number of people. That has now begun to change. A number of promising new approaches are now being developed and some will soon be ready for testing in humans. One major aim of Enroll-HD is to support these new clinical trials of novel drugs that are being developed specifically for HD by helping to build the infrastructure needed to do clinical trials as quickly as possible. In this video "Postcard from Palm Springs 2014", HD family advocate and former NBC reporter Charles Sabine offers an overview of new HD research and discoveries presented at the 2014 HD Therapeutics Conference, hosted by CHDI in Palm Springs, California.
Now Under DevelopmentSeveral new methods to lower the amount of mutant huntingtin in the body are now being studied. Many of them involve gene silencing, which are various ways to prevent the mutant gene from producing the disease-causing protein. These techniques are exciting because they are a whole new type of drug. Different versions of gene silencing might prevent or treat many different types of disease. For the most part, though, they are so new that they haven’t been widely tested in patients yet. One of these methods, antisense oligonucleotides (or ASOs), uses short stretches of DNA to zero in on the HD gene to prevent mutant huntingtin protein being produced, a so-called “huntingtin-lowering” strategy. In September 2015, the California biotech company Ionis Pharmaceuticals, in partnership with the Swiss pharmaceutical company Roche, began the first small clinical trial of huntingtin-lowering in people. This early-stage trial, with just 36 people, will explore whether the treatment is safe.
Another new drug has already moved on to larger trials: A phosphodiesterase inhibitor (PDE inhibitor). In general, PDE inhibitors change the activity levels of nerve cells. One drug, which inhibits a specific type of PDE called PDE-10A, was tested previously in people with schizophrenia, but evidence from mouse models suggests it might be more effective in HD. The pharmaceutical company Pfizer conducted a preliminary test of its PDE-10A inhibitor in a 28-day study of 37 people with HD. The drug seemed to be well-tolerated, without unexpected side effects or major safety worries. Even better, it seemed to improve volunteers’ performance on a test of motivation. Based on these encouraging results, Pfizer launched a bigger, more ambitious study. By the spring of 2016, its “Amaryllis” study, which will test the same drug for six months in 266 people, was fully enrolled, with all participants signed up.